此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL) (Aurora)

2026年7月8日 更新者:Lu Huaiwu、Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

A Prospective, Open-label, Randomized, Controlled, Non-inferiority Phase II Study Comparing HAL-PDT With Deferred Surgery Versus Immediate Surgery in Subjects With High-grade Squamous Intraepithelial Lesions (HSIL)

High-grade squamous intraepithelial lesions (HSIL), encompassing cervical intraepithelial neoplasia grade 2 (CIN2) with p16 positivity and grade 3 (CIN3), are precancerous conditions that require effective intervention. This Phase II study aims to comprehensively evaluate the efficacy, safety, and impact on quality of life of hexaminolevulinate photodynamic therapy (HAL-PDT) with deferred surgery compared to immediate surgical treatment in subjects with HSIL.

This is a prospective, open-label, randomized, controlled, non-inferiority trial. A total of 230 subjects are planned to be enrolled, with 115 subjects allocated to each treatment group (HAL-PDT with Deferred Surgery or Immediate Surgery ).

The primary endpoint is the pathological regression rate at 12 months, defined as histological findings of normal tissue or low-grade squamous intraepithelial lesions (LSIL) via colposcopy-directed biopsy. Key secondary endpoints include Human Papillomavirus (HPV) clearance rates at 6 and 12 months, pathological regression rate at 6 months, quality of life assessed by the EORTC QLQ-CX24 questionnaire, safety profiles (incidence, severity, and duration of AEs and SAEs, as well as their relationship to the study treatments), and the proportion of subjects developing cervical cancer within 12 months.

研究概览

详细说明

High-grade squamous intraepithelial lesions (HSIL), encompassing cervical intraepithelial neoplasia grade 2 (CIN2) with p16 positivity and grade 3 (CIN3), are well-established precursors to invasive cervical cancer. Immediate excisional procedures such as loop electrosurgical excision procedure (LEEP) or cold knife conization remain the standard of care; however, they are associated with significant long-term morbidities, including cervical stenosis, cervical incompetence, and adverse obstetric outcomes in women of childbearing age. Hexaminolevulinate photodynamic therapy (HAL-PDT) is a non-invasive, tissue-preserving modality that offers a potential alternative.

This Phase II trial is designed to test the hypothesis that HAL-PDT (HAL-PDT Q2W×6 ) with deferred surgery achieves a 12-month pathological regression rate non-inferior to that of immediate surgery, while providing a favorable safety and quality-of-life profile.

A total of 230 subjects are planned for enrollment, with 115 allocated to each treatment arm. The primary efficacy analysis will be performed on both the Intention-to-Treat (ITT) and Per-Protocol (PP) populations to test the non-inferiority margin, which is pre-specified based on clinically acceptable thresholds. Safety analyses will be conducted on the Safety Set (SS).

研究类型

介入性

注册 (估计的)

230

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Fujian
      • Fuzhou、Fujian、中国、350001
        • Fujian Medical University Union Hospital
        • 接触:
          • Ethics Committee Administrator
          • 电话号码:0591-83357896
          • 邮箱:fjxhe_irb@163.com
        • 首席研究员:
          • Dezhao Chen, MD, PhD
      • Fuzhou、Fujian、中国、350005
        • The First Affiliated Hospital of Fujian Medical University
        • 接触:
          • Ethics Committee Administrator
          • 电话号码:0591-87982001
          • 邮箱:fdyy_irb@163.com
        • 首席研究员:
          • Lihong Chen, MD, PhD
      • Xiamen、Fujian、中国、361001
        • Xiamen Maternity and Child Healthcare Hospital
        • 接触:
          • Ethics Committee Administrator
          • 电话号码:0592-2662920
          • 邮箱:xmfyllwyh@163.com
        • 首席研究员:
          • Qing Li, MD, PHD
      • Xiamen、Fujian、中国、361003
        • he First Affiliated Hospital of Xiamen University
        • 接触:
        • 首席研究员:
          • Qionghua Chen, MD, PHD
    • Guangdong
      • Foshan、Guangdong、中国、528000
        • The First People's Hospital of Foshan
        • 接触:
        • 首席研究员:
          • Lijiang Xu, MD, PHD
      • Foshan、Guangdong、中国、528300
        • Foshan Shunde Maternal and Child Health Hospital
        • 接触:
        • 首席研究员:
          • Jinzhi Huang, MD, PHD
      • Guangzhou、Guangdong、中国、510280
        • Zhujiang Hospital, Southern Medical University
        • 接触:
          • Ethics Office Administrator
          • 电话号码:+86-020-62783372
          • 邮箱:zjyygcp@163.com
        • 首席研究员:
          • Xuefeng Wang, MD, PhD
      • Guangzhou、Guangdong、中国、510010
        • Guangdong Women and Children Hospital
        • 接触:
        • 首席研究员:
          • Xiaoli Sun, MD, PHD
      • Guangzhou、Guangdong、中国、510095
        • The Affiliated Cancer Hospital of Guangzhou Medical University
        • 接触:
        • 首席研究员:
          • Bin Wen, MD, PhD
      • Guangzhou、Guangdong、中国、510120
        • Guangdong ProvincialHospital of Chinese Medicine
        • 接触:
          • Administrator Ethics Committee
          • 电话号码:020-81887233-35943
          • 邮箱:Ilbgs@gzucm.edu.cn
        • 首席研究员:
          • Jing Xiao, MD, PhD
      • Guangzhou、Guangdong、中国、510180
        • Guangzhou First People's Hospital (The Second Affiliated Hospital of South China University of Technology)
        • 接触:
          • Ethics Committee Administrator
          • 电话号码:020-81045412
          • 邮箱:MEC_GZSY@126.com
        • 首席研究员:
          • Yan Kuang, MD, PhD
      • Guangzhou、Guangdong、中国、510317
        • Guangdong Second Provincial GeneralHospital (Guangdong Provincial Emergency Hospital)
        • 接触:
          • Administrator Clinical Research Office
          • 电话号码:+86-20-89168338
          • 邮箱:gdech_irb@163.com
        • 首席研究员:
          • Xiafei Fu, MD, PhD
      • Guangzhou、Guangdong、中国、510405
        • The First AffiliatedHospital, Guangzhou University ofTraditional Chinese Medicine
        • 接触:
          • Ethics Committee Administrator
          • 电话号码:+86-20-36588667
          • 邮箱:gztcmlunli@163.com
        • 首席研究员:
          • Sijin Li, MD, PhD
      • Guangzhou、Guangdong、中国、510623
        • Guangzhou Women and Children's Medical Center (The Affiliated Women and Children's Medical Center of Guangzhou Medical University)
        • 接触:
          • Ethics Committee Administrator
          • 电话号码:020-81886332
          • 邮箱:gzwc_irb@163.com
        • 首席研究员:
          • Kun Shi, MD, PhD
      • Guangzhou、Guangdong、中国、511400
        • Panyu Central Hospital Affiliated to Guangzhou Medical University
        • 接触:
        • 首席研究员:
          • Xiang Yang, MD, PhD
      • Shenzhen、Guangdong、中国、518036
        • Peking University Shenzhen Hospital
        • 接触:
        • 首席研究员:
          • Zhihong Liu, MD, PhD
      • Shenzhen、Guangdong、中国、518031
        • Shenzhen Maternity and Child Health Hospital
        • 接触:
        • 首席研究员:
          • Ping Jin, MD, PHD
      • Zhongshan、Guangdong、中国、510080
        • The First Affiliated Hospital, Sun Yat-sen University
        • 接触:
        • 首席研究员:
          • Mian He, MD, PHD
        • 首席研究员:
          • Junxiu Liu, MD, PHD
    • Guangxi
      • Nanning、Guangxi、中国、530021
        • The First Affiliated Hospital of Guangxi Medical University
        • 接触:
        • 首席研究员:
          • Jiangtao Fan, MD, PhD
      • Nanning、Guangxi、中国、530000
        • Guangxi Zhuang Autonomous Region Maternal and Child Health Hospital
        • 接触:
        • 首席研究员:
          • Chunqiu Xiong, MD, PHD
    • Guangzhou
      • Dongguan、Guangzhou、中国、523000
        • Dongguan Maternal and Child Health Care Hosptial
        • 接触:
        • 首席研究员:
          • Ping Zhou, MD, PHD
    • Henan
      • Zhengzhou、Henan、中国、450052
        • The First Affiliated Hospital of Zhengzhou University
        • 接触:
          • Ethics Committee Administrator
          • 电话号码:0371-66278510
          • 邮箱:zdyyllwy@163.com
        • 首席研究员:
          • Liping Han, MD, PhD
    • Jiangsu
      • Nanjing、Jiangsu、中国、210029
        • The First Affiliated Hospital with Nanjing Medical University (Jiangsu Provincial People's Hospital)
        • 接触:
          • Ethics Committee Administrator
          • 电话号码:025-68136360
          • 邮箱:jsphkj@163.com
        • 首席研究员:
          • Xiaoling Ma, MD, PhD
    • Jinlin
      • Changchun、Jinlin、中国
        • The First Hospital of Jilin University
        • 接触:
        • 首席研究员:
          • Songling Zhang, MD, PHD
    • Liaoning
      • Shenyang、Liaoning、中国、110016
        • The General Hospital of Northern Theater Command of the Chinese People's Liberation Army
        • 接触:
        • 首席研究员:
          • Lipeng Pei, MD, PhD
    • Shanxi
      • Taiyuan、Shanxi、中国、030000
        • Shanxi Provincial People's Hospital
        • 接触:
        • 首席研究员:
          • Yuping Suo, MD, PHD
    • Sichuan
      • Chengdu、Sichuan、中国、610041
        • The West China Second University Hospital of Sichuan University
        • 接触:
        • 首席研究员:
          • Yuedong He, MD, PHD
    • Zhejiang
      • Hangzhou、Zhejiang、中国、310022
        • Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
        • 接触:
        • 首席研究员:
          • Yichen Wang, MD, PhD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Voluntarily participate in this clinical study, fully understand the study content, procedures, and potential adverse reactions, and be able to sign the written informed consent form.
  • Able to complete the study in accordance with the study protocol.
  • Subject age ≥18 years.
  • Presence of High-Grade Squamous Intraepithelial Lesion (HSIL) (CIN2 P16 positive/CIN3), specifically: HSIL with histopathological diagnosis of grade II/III (CIN2 P16 positive/CIN3) within 3 months prior to the first treatment.
  • Adequate colposcopy, including: (a) Complete visibility of the cervical transformation zone, including the squamocolumnar junction; (b) Complete visibility of lesion margins.
  • The investigator determines that non-surgical treatment is acceptable for the participant.
  • The investigator determines that the cervical size is suitable for placement of the HAL-PDT device.
  • Meets the following conditions: Women of childbearing potential (WOCBP) must have a negative serum pregnancy test result prior to the start of treatment. No plan for pregnancy during the study period; no sexual activity or use of effective and reliable contraception from the end of the last menstrual period to the start of the study, and agreement to use condoms for barrier contraception during the study period. WOCBP is defined as a female who has experienced menarche, has not undergone hysterectomy or bilateral oophorectomy, and has not reached natural menopause (i.e., no menstruation at all for the past 24 consecutive months).

Exclusion Criteria:

  • Cervical adenocarcinoma in situ or other glandular lesions, invasive cervical cancer, or suspected malignant lesions.
  • CIN2 with P16 negative.
  • Lesions extending to the vaginal wall, cervical canal, or vaginal fornix, or lesions located on the vulva.
  • Prior physical or surgical treatment to the cervix resulting in incomplete cervical structure (e.g., cold knife conization), or receipt of physical or surgical therapy for CIN2 or CIN3 after the current histopathological diagnosis.
  • The first study treatment day falls within 7 half-lives of the last antiviral medication.
  • Severe pelvic inflammatory disease, severe cervicitis, or other severe gynecological infectious diseases found on colposcopic or clinical examination.
  • Investigator judges that vaginal bleeding during treatment may affect treatment outcomes.
  • Receipt of any inactivated vaccine within 2 weeks prior to the first treatment, or any live vaccine within 4 weeks prior to the first treatment.
  • Previous severe cardiovascular, cerebrovascular, neurological, psychiatric, endocrine, or hematopoietic disease that has not been cured; known severely compromised immune function, or need for long-term use of corticosteroids or immunosuppressants; history of malignancy within 5 years.
  • History of clinically significant immunosuppression or confirmed autoimmune disease; or primary immunodeficiency.
  • Known or newly identified active sexually transmitted diseases (STDs), including but not limited to HIV, syphilis, genital herpes, unless adequately treated and tested negative before study treatment.
  • Presence of a cardiac pacemaker.
  • Suspected or known porphyria, or known allergy to the study drug, its chemically similar compounds, or photosensitizers.
  • Allergy to silicone.
  • Pregnant or breastfeeding women.
  • Delivery or miscarriage within 6 weeks prior to enrollment.
  • Participation in any other clinical trial within 30 days prior to study treatment.
  • Poor compliance or judged by the investigator to be unsuitable for participation in this clinical study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Hexaminolevulinate Photodynamic Therapy (HAL-PDT) with Deferred Surgery
Subjects receive Hexaminolevulinate Photodynamic Therapy (HAL-PDT) once every 2 weeks (Q2W) for a total of 6 treatment sessions. At 6 months after the first treatment, participants undergo colposcopy-directed cervical biopsy and HPV testing to assess treatment response. Those who achieve pathological remission (normal or LSIL) enter follow-up without surgery. Those who do not achieve remission (persistent HSIL or disease progression) receive standard surgical treatment (LEEP or CKC) within 4 weeks of the 6-month assessment.
HAL-PDT is a drug-device combination product. The drug is hexaminolevulinate hydrochloride (HAL) 5% ointment. The device is a single-use cervical light delivery device (CL7) with integrated red LEDs. The ointment is applied into the device cup, placed against the cervix for 5 hours of drug absorption, then automatically delivers 125 J/cm² photodynamic therapy for 4 hours and 36 minutes. Total in-situ time is 11-24 hours. Patients remove the device themselves. Treatment regimen: one session every 2 weeks for a total of 6 sessions (Q2W × 6).
有源比较器:Immediate Surgery
Participants with histologically confirmed HSIL (CIN2 P16 positive/CIN3) receive standard surgical treatment (LEEP or CKC) per routine clinical practice. Follow-up assessments include HPV testing and colposcopy-directed cervical biopsy at 6 months and 12 months post-surgery to evaluate pathological remission and HPV clearance rates. Safety monitoring is conducted from signing of informed consent through the end of study.
Subjects undergo immediate surgical excision of the cervical lesion via either Loop Electrosurgical Excision Procedure (LEEP) or Cold Knife Conization (CKC), as determined by the investigator based on the subject's individual lesion characteristics, size, and clinical presentation, following standard institutional surgical protocols.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Histopathological regression rate at 12 months
大体时间:12 months after the first treatment
Proportion of participants with pathological remission on colposcopy-directed cervical biopsy at 12 months after the first treatment. Pathological remission is defined as histopathological finding of normal tissue or low-grade squamous intraepithelial lesion (LSIL)
12 months after the first treatment

次要结果测量

结果测量
措施说明
大体时间
Pathological remission rate at 6 months
大体时间:6 months after the first treatment
Proportion of participants with pathological remission on colposcopy-directed cervical biopsy at 6 months after the first treatment. Pathological remission is defined as histopathological finding of normal tissue or low-grade squamous intraepithelial lesion (LSIL).
6 months after the first treatment
HPV baseline clearance rate at 12 months
大体时间:12 months after the first treatment
Proportion of participants with clearance of baseline high-risk HPV subtypes at 12 months after the first treatment. HPV clearance is defined as undetectable of the same high-risk HPV subtype(s) that were present at baseline.
12 months after the first treatment
Incidence of cervical cancer at 12 months
大体时间:12 months after the first treatment
Proportion of participants with histologically confirmed cervical cancer (any stage) diagnosed within 12 months after the first treatment.
12 months after the first treatment
Human Papillomavirus (HPV) baseline clearance rate at 6 months
大体时间:6 months after the first treatment
Proportion of participants with clearance of baseline high-risk Human Papillomavirus (HPV) subtypes at 6 months after the first treatment. HPV clearance is defined as undetectable of the same high-risk HPV subtype(s) that were present at baseline.
6 months after the first treatment
Quality of life assessed by EORTC QLQ-CX24
大体时间:12 months after the first treatment
Quality of life assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Cervical Cancer Module (EORTC QLQ-CX24). Scores for each domain are linearly transformed to a 0-100 scale. For global health status and functional domains, a higher score indicates a better outcome (better quality of life/function). For symptom scales, a higher score indicates a worse outcome (more severe symptoms).
12 months after the first treatment
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
大体时间:From informed consent through 12 months after the first treatment
Incidence, type, severity (mild, moderate, severe), duration, and relatedness to photodynamic therapy and/or surgical treatment of adverse events (AEs) and serious adverse events (SAEs) occurring from signing of informed consent through the end of study follow-up.
From informed consent through 12 months after the first treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年7月1日

初级完成 (估计的)

2029年6月16日

研究完成 (估计的)

2029年6月16日

研究注册日期

首次提交

2026年6月21日

首先提交符合 QC 标准的

2026年6月21日

首次发布 (实际的)

2026年6月25日

研究记录更新

最后更新发布 (实际的)

2026年7月9日

上次提交的符合 QC 标准的更新

2026年7月8日

最后验证

2026年7月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅